T1	Condition 0 9	Pregnancy
T2	Observation 14 28	breast feeding
*	OR T2 T1
T3	Observation 38 63	Estimated life expectancy
T4	Value 64 74	<12 months
R1	Has_value Arg1:T3 Arg2:T4	
T5	Mood 77 86	Scheduled
T6	Procedure 87 100	major surgery
T7	Temporal 101 121	in the next 6 months
R2	Has_temporal Arg1:T6 Arg2:T7	
R3	Has_mood Arg1:T6 Arg2:T5	
T10	Measurement 424 427	WHO
T11	Value 428 448	group II, III, IV, V
T12	Condition 449 451	PH
R4	Has_value Arg1:T10 Arg2:T11	
R5	AND Arg1:T12 Arg2:T10	
T13	Condition 460 477	Renal dysfunction
T14	Qualifier 453 459	Severe
R6	Has_qualifier Arg1:T13 Arg2:T14	
T15	Measurement 479 482	Ccr
T16	Value 482 492	<30 ml/min
T17	Scope 453 477	Severe Renal dysfunction
R7	Subsumes Arg1:T17 Arg2:T15	
R8	Has_value Arg1:T15 Arg2:T16	
T18	Measurement 495 515	Blood platelet count
T19	Value 515 525	<100,000/L
R9	Has_value Arg1:T18 Arg2:T19	
T20	Observation 527 545	Expected life span
T21	Value 545 553	<6-month
R10	Has_value Arg1:T20 Arg2:T21	
T22	Condition 555 580	Systematical inflammation
T23	Condition 582 598	Malignant cancer
T24	Condition 603 627	Tricuspid valve stenosis
T25	Condition 629 659	Supra-pulmonary valve stenosis
*	OR T24 T25
T26	Condition 661 669	Allergic
T27	Drug 673 686	studied drugs
T28	Drug 673 680;690 705	studied metal materials
*	OR T27 T28
T29	Scope 673 705	studied drugs or metal materials
R11	Has_scope Arg1:T26 Arg2:T29	
T9	Temporal 288 296	Previous
T30	Procedure 324 362	treatment with an investigational drug
T31	Drug 342 362	investigational drug
R12	multi Arg1:T30 Arg2:T31	
R13	Has_temporal Arg1:T30 Arg2:T9	
T32	Observation 297 320	enrolment in this study
*	OR T30 T32 T33
R14	Has_temporal Arg1:T32 Arg2:T9	
T33	Device 366 372	device
R15	Has_temporal Arg1:T33 Arg2:T9	
T8	Observation 124 156	Inability to follow the protocol
T34	Observation 124 136;161 195	Inability to comply with follow-up requirements
*	OR T34 T8
